Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates t…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.53 | $-0.50 |
| Estimado | $-0.63 | $-0.57 | $-0.59 | $-0.06 |
| Sorpresa | — | — | +10.2% | -733.3% |
| Métrica | MSLE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -89.5% | -39.2% | -50.3% |
| ROA | -78.0% | -30.9% | -47.0% |
| Current Ratio | 7.77 | 2.73 | +5.04 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -78.0% | — |
| ✗Flujo de caja operativo positivo | −$24M | −$18M |
| ✗Rentabilidad sobre activos al alza | -78.0% | -40.7% |
| ✓Caja operativa/activos supera al ROA | -74.0% | ROA -78.0% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 7.77 | 14.16 |
| ✗Sin aumentar el nº de acciones | 15M | 10M |
| –Margen bruto al alza | — | — |
| –Rotación de activos al alza | — | — |
| Calidad del negocio | FY25 |
|---|---|
| ✗ROCE > 10 % | -95.2% |
Satellos Bioscience Inc. cotiza a 6.46 USD y tiene una capitalización bursátil de $137M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud